Abstract 10221: Evaluating the Effectiveness of Rosuvastatin in Preventing the Progression of Diastolic Dysfunction in Aortic Stenosis: A Substudy of the Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin (ASTRONOMER) Study
Background: Tissue Doppler imaging (TDI) is a noninvasive echocardiographic method for the diagnosis of diastolic dysfunction in patients with varying degrees of aortic stenosis (AS). Little is known however on the utility of TDI in the serial assessment of diastolic abnormalities in AS.
Objectives: The aim of the current proposal was to examine whether treatment with rosuvastatin was successful in improving diastolic abnormalities in patients enrolled in the Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin study (ASTRONOMER), a multicentre study to assess the effects of rosuvastatin on the progression of AS.
Methods and Results: The study population included 168 patients (56±13 years) whose AS severity was categorized based on peak velocity at baseline (Group I: 2.5–3.0 m/s; Group II: 3.1–3.5 m/s; Group III: 3.6–4.0 m/s). Baseline and follow-up hemodynamics, LV dimensions and diastolic functional parameters were evaluated in all three groups. At baseline, the aortic valve peak gradients were 31±3 mm Hg (Group I), 41±4 mm Hg (Group II) and 56±4 mm Hg (Group III) respectively (Table 1). There was increased diastolic dysfunction from baseline to follow-up in each of the placebo and rosuvastatin groups. In patients with increasing severity of AS, the lateral E' was lower and the E/E' (as an estimate of increased left ventricular end-diastolic pressure) was higher at baseline (p<0.05). However, there was no difference in progression of diastolic dysfunction from baseline to follow-up at 3.5 years between patients in all three predefined groups with AS who received placebo versus rosuvastatin (Table 1).
Conclusions: In patients with mild to moderate asymptomatic AS, rosuvastatin did not prevent the progression of diastolic dysfunction. Table 1: Diastolic echocardiographic parameters at baseline and followup (n=168)
- © 2010 by American Heart Association, Inc.